Common questions about Repatha (FAQ)
Q: What specific conditions or types of high cholesterol is Repatha approved to treat?
Repatha (evolocumab) is indicated, according to official regulatory documents, for use in adults and pediatric patients ge 10 years old with Primary Hyperlipidemia, which includes inherited conditions like Familial Hypercholesterolemia (FH). It is also approved for use in adults who have Established Atherosclerotic Cardiovascular Disease (ASCVD) to help reduce the risk of major cardiovascular events like heart attack and stroke. It is intended for use in addition to a healthy diet.
Q: How does Repatha differ from statins in the way it lowers cholesterol?
Official information describes Repatha as a monoclonal antibody that works by targeting and blocking the protein PCSK9. This action allows the liver to clear more LDL cholesterol (often called 'bad' cholesterol) from the bloodstream. This mechanism differs from statins, which are described as working by inhibiting an enzyme involved in cholesterol synthesis.
Q: How quickly can a person expect to see a change in their LDL-C level after starting Repatha?
According to the official product information, the initial effect of Repatha on lowering LDL cholesterol levels may be measured as early as four weeks after starting the treatment. Individual responses to the medicine may vary.
Q: What happens to cholesterol levels if a person stops using Repatha?
If Repatha treatment is stopped, official information suggests that LDL cholesterol levels will gradually return toward the levels measured before treatment started. This return to baseline is based on the drug's properties and how it is eliminated from the body.
Q: Does Repatha have any reported side effects related to liver function?
Regulatory clinical trials reported no significant difference in the incidence of abnormal liver function tests (specifically, elevated liver enzymes) compared to placebo. Caution, however, is formally advised for patients with severe hepatic impairment due to limited study data in this population.
Q: Can Repatha affect blood sugar levels or increase the risk of developing diabetes?
In the major cardiovascular outcomes trial, the rate of new-onset diabetes mellitus was reported more frequently in patients receiving Repatha compared to those receiving a placebo. Diabetes mellitus was generally classified as a common adverse reaction in the clinical trials.
Q: Does taking Repatha require any specific dietary changes, or is it meant to be used with a standard heart-healthy diet?
Official documentation indicates that the medicine is meant to be used alongside dietary measures, such as maintaining a low-fat diet. Repatha is formally approved as an adjunct (or addition) to diet and other lipid-lowering therapies.
Q: What evidence is there regarding the safety of achieving very low LDL cholesterol levels with Repatha?
Clinical trial evidence reported that the incidence of serious adverse events was similar in patients who achieved very low LDL cholesterol levels compared to the incidence in those with higher levels. The research, therefore, did not detect a clear, new safety concern in these patients during the study period.
Q: Is dizziness a reported side effect of Repatha, and how often does it occur?
According to official documentation on adverse reactions, dizziness was reported during clinical trials. It was noted to occur in ge 3% of patients treated with Repatha, and this occurrence was more frequent than what was observed in the placebo groups during the 52-week trial.
Q: How is the safety of Repatha monitored during long-term use?
Official information indicates that the drug's safety profile has been followed for several years in long-term open-label extension studies. These studies continuously monitored patients for potential side effects, and no new or unexpected safety signals were noted during that extended period.
Q: Why does official documentation mention an increased risk of urinary tract infections (UTIs) with Repatha?
Official documentation reports that urinary tract infection (UTI) was observed during clinical trials. It was listed as an adverse reaction occurring in ge 3% of patients treated with Repatha, and this rate was higher than the rate observed in patients receiving a placebo.
Q: How do doctors decide if Repatha is the appropriate treatment for a patient?
The usage of Repatha is based on official regulatory indications, which define the patient populations for whom the medicine is intended, such as individuals with certain inherited forms of high cholesterol or established cardiovascular disease. It is formally indicated as an adjunct to diet and other lipid therapies.
Q: Is it correct that Repatha is only available as a brand-name drug and not a generic?
Repatha (evolocumab) is classified as a specialized biologic agent. Currently, official sources confirm that it is only available as the brand-name product and there are no generic versions or FDA-approved biosimilars available.
Q: Is Repatha intended to replace other cholesterol-lowering medicines, or is it used in addition to them?
Official documentation indicates that Repatha is intended to be an adjunct therapy, meaning it is used in addition to other existing treatments like diet and statins, or alone if a patient cannot tolerate statins. It is not generally intended to replace other lipid-lowering therapies.
Q: Is Repatha a short-term or long-term medication for cholesterol management?
Based on the dosing schedule (every two weeks or monthly) and the design of the clinical trials, the drug is used in the context of long-term management for chronic lipid disorders and cardiovascular risk.
Q: Can a patient use Repatha while taking common blood thinners or diabetes medications?
Official documentation states that Repatha is primarily cleared through protein breakdown and does not rely on the CYP450 enzyme system, which minimizes the potential for interactions with many other drugs. However, formal interaction studies specifically involving common blood thinners or diabetes medications are not detailed in the regulatory label.
Q: Is Repatha generally safe for elderly patients (75 years and older)?
Official clinical trial data reported no overall differences in safety or effectiveness observed in patients over 65 years of age compared to younger individuals. However, the official documentation notes that some older individuals may exhibit greater sensitivity to medications.
Q: Are there different Repatha devices (pen, syringe, infusor), and do they deliver the same medicine?
Official documentation confirms Repatha is supplied in different single-dose delivery systems, which include autoinjector pens, prefilled syringes, and a specific on-body infusor system. All of these devices contain the same active ingredient, evolocumab.
Q: What is the difference between the 140 mg dose and the 420 mg dose?
The official product information provides different frequency patterns for these doses. The 140 mg dose is generally administered every two weeks. The 420 mg dose is generally administered once monthly, but specific high-risk conditions may involve a frequency of every two weeks.
Q: What does the term 'cardiovascular event risk reduction' mean in the context of Repatha?
In the context of the clinical trials, the reduction of major adverse cardiovascular events (MACE) was measured as a composite outcome. This included preventing the first occurrence of events such as a heart attack (myocardial infarction), stroke, cardiovascular death, or the need for a revascularization procedure.
Q: What should a person do if they notice the liquid in the injection pen is cloudy or discolored?
Official guidance requires patients to visually inspect the solution before use. The product is specified for use only if the solution is clear to opalescent, colorless to pale yellow. If the liquid appears cloudy, discolored, or contains particles, it must be discarded.
Q: Does the efficacy of Repatha change depending on a patient's age or gender?
Official documents state that dosage adjustment is not required based on either age or gender. This suggests that the expected effectiveness of the drug is not specifically dependent on these factors.
